Arrivent Biopharma, Common Stock Today
| AVBP Stock | 29.11 0.37 1.29% |
Performance4 of 100
| Odds Of DistressLess than 49
|
ArriVent BioPharma, is selling at 29.11 as of the 28th of November 2024; that is 1.29 percent up since the beginning of the trading day. The stock's last reported lowest price was 28.29. ArriVent BioPharma, has 49 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for ArriVent BioPharma, Common are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of December 2022 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of January 2024 | Category Healthcare | Classification Health Care |
ArriVent BioPharma, is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 33.59 M outstanding shares of which 3.54 M shares are presently shorted by private and institutional investors with about 10.97 trading days to cover. More on ArriVent BioPharma, Common
Moving against ArriVent Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
ArriVent Stock Highlights
| Chairman, CoFounder | Zhengbin Yao | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
ArriVent BioPharma, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ArriVent BioPharma,'s financial leverage. It provides some insight into what part of ArriVent BioPharma,'s total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
ArriVent BioPharma, Common (AVBP) is traded on NASDAQ Exchange in USA. It is located in 18 Campus Boulevard, Newtown Square, PA, United States, 19073 and employs 40 people. ArriVent BioPharma, is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 798 M. ArriVent BioPharma, conducts business under Biotechnology sector and is part of Health Care industry. The entity has 33.59 M outstanding shares of which 3.54 M shares are presently shorted by private and institutional investors with about 10.97 trading days to cover.
ArriVent BioPharma, generates negative cash flow from operations
Check ArriVent BioPharma, Probability Of Bankruptcy
Ownership AllocationArriVent BioPharma, holds a total of 33.59 Million outstanding shares. Over half of ArriVent BioPharma,'s outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check ArriVent Ownership Details
ArriVent BioPharma, Historical Income Statement
ArriVent Stock Against Markets
ArriVent BioPharma, Corporate Executives
Elected by the shareholders, the ArriVent BioPharma,'s board of directors comprises two types of representatives: ArriVent BioPharma, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ArriVent. The board's role is to monitor ArriVent BioPharma,'s management team and ensure that shareholders' interests are well served. ArriVent BioPharma,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ArriVent BioPharma,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Winston MBA | CFO Treasurer | Profile | |
| Robin MA | CoFounder COO | Profile |
Already Invested in ArriVent BioPharma, Common?
The danger of trading ArriVent BioPharma, Common is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ArriVent BioPharma, is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ArriVent BioPharma,. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ArriVent BioPharma, is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for ArriVent Stock Analysis
When running ArriVent BioPharma,'s price analysis, check to measure ArriVent BioPharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma, is operating at the current time. Most of ArriVent BioPharma,'s value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma,'s price. Additionally, you may evaluate how the addition of ArriVent BioPharma, to your portfolios can decrease your overall portfolio volatility.